Taysha Gene Therapies Debt to Equity Ratio 2020-2024 | TSHA
Current and historical debt to equity ratio values for Taysha Gene Therapies (TSHA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Taysha Gene Therapies debt/equity for the three months ending June 30, 2024 was 0.35.
| Taysha Gene Therapies Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.09B |
$0.11B |
0.84 |
| 2024-03-31 |
$0.10B |
$0.05B |
1.84 |
| 2023-12-31 |
$0.10B |
$0.08B |
1.31 |
| 2023-09-30 |
$0.25B |
$-0.05B |
-4.99 |
| 2023-06-30 |
$0.12B |
$-0.04B |
-3.20 |
| 2023-03-31 |
$0.12B |
$-0.02B |
-7.80 |
| 2022-12-31 |
$0.13B |
$0.00B |
132.06 |
| 2022-09-30 |
$0.10B |
$0.01B |
9.02 |
| 2022-06-30 |
$0.11B |
$0.03B |
3.35 |
| 2022-03-31 |
$0.12B |
$0.05B |
2.27 |
| 2021-12-31 |
$0.12B |
$0.10B |
1.24 |
| 2021-09-30 |
$0.10B |
$0.14B |
0.72 |
| 2021-06-30 |
$0.06B |
$0.19B |
0.30 |
| 2021-03-31 |
$0.02B |
$0.22B |
0.09 |
| 2020-12-31 |
$0.01B |
$0.25B |
0.03 |
| 2020-09-30 |
$0.01B |
$0.27B |
0.04 |
| 2020-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2020-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2019-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.314B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
